STAT News

STAT+: Pharmalittle: We’re reading about a setback for Eyepoint, a win for Amylyx, and more

Eyepoint disclosed that a Phase 3 trial of its experimental treatment for a common cause of age-related blindness fell short of its primary goal

Por STAT News

1 minuto de lectura
Compartir
STAT+: Pharmalittle: We’re reading about a setback for Eyepoint, a win for Amylyx, and more
STAT+: Pharmalittle: We’re reading about a setback for Eyepoint, a win for Amylyx, and more

¿Tiene noticias que compartir con el sector de eventos?

Envíe un comunicado de prensa o una noticia y llegue a miles de profesionales del sector de eventos.

Contáctenos→

Más en Health Tech

Perspectivas relacionadas